#China #Tianjin #Peptide Production #Asymchem #TIDES

Asymchem Introduces Next-Generation TIDES Commercial Supply Matrix

In a significant development within the pharmaceutical manufacturing sector, Asymchem, a prominent global contract development and manufacturing organization (CDMO), has unveiled its innovative integrated commercial supply matrix dedicated to TIDES, which encompasses peptides and oligonucleotides. This announcement was made at the company’s TJ4 facility, marking a pivotal step towards enhancing the capacity and efficiency of drug production processes.

Comprehensive Integration of Manufacturing Capabilities

The newly launched commercial supply matrix combines expanded active pharmaceutical ingredient (API) manufacturing capabilities with refined drug product facilities and cutting-edge technologies tailored for TIDES processes. The initiative aims to deliver a seamless transition from molecule to market, establishing Asymchem’s TJ4 site as a world-class leader in TIDES production.

The installation of new solid-phase peptide synthesis (SPPS) reactors at the TJ4 site has resulted in a remarkable enhancement of production capacity, pushing total SPPS reactor volume beyond 45,000 liters. As a result, Asymchem is set to achieve an impressive annual peptide production capacity exceeding 22.5 metric tons. This robust increase addresses the surge in global demand for peptide-based therapeutics. Anticipated further expansions of SPPS capacity are projected to reach approximately 69,000 liters by the end of 2026, ensuring long-term supply assurance.

Adapting to Growing Market Needs

In addition to peptides, Asymchem is proactive in scaling its oligonucleotide manufacturing platform. Currently, the production capacity for oligonucleotides stands at a minimum of 180 mol/year, with plans for strategic phase-based expansions. This phased approach allows for efficient scaling to support growing clinical programs and commercial demand, ensuring consistent batch sizes and reliable supply commitments.

Bridging the Gap: API to Patient

To further enhance the API manufacturing framework, Asymchem has strategically aligned its drug product capabilities. The company has inaugurated a new 6,000 m² drug product manufacturing facility, which focuses on producing pre-filled syringes and cartridges. The operational pre-filled syringe line can support batch sizes up to 150,000 units and boasts an annual production capacity of around 45 million units. Complementing these capabilities, the cartridge manufacturing workshop is expected to commence production by June 2026, targeting an annual capacity of up to 100 million units.

Empowering Innovations with Next-Generation Technology

Asymchem’s strategy is not only rooted in capacity but also in leveraging next-generation technologies to optimize its manufacturing footprint. The company has developed a robust upstream technology portfolio, including Tag-assisted liquid-phase peptide/oligonucleotide synthesis and innovative stirred-bed technology. These advancements enable continuous and solvent-efficient synthesis, catering to the evolving needs of TIDES manufacturing.

Furthermore, Asymchem emphasizes efficiency and control in downstream processing. State-of-the-art technologies such as Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) and an AI-assisted Process Analytical Technology (PAT) platform highlight its commitment to refining purification processes. Notably, Asymchem is among the few organizations worldwide to implement commercial-scale MCSGP, asserting its leadership in advanced purification technologies for TIDES.

The Role of AI in Manufacturing Efficiency

Artificial intelligence is a cornerstone of Asymchem's TIDES development and manufacturing continuum. From route selection to analytical method development, AI enhances decision-making effectiveness, reduces development uncertainties, and accelerates timelines. This commitment to integrating AI across the TIDES framework empowers Asymchem to achieve predictable and scalable outcomes for its partners, ensuring a shared journey from innovative discovery to commercial success.

A Coordinated Global Network

Operating a globally coordinated research and development (RD) and manufacturing network spanning China, the US, and the UK, Asymchem offers fully integrated upstream and downstream capabilities for TIDES. With critical supply components under in-house control, such as enzymes and amino acids, Asymchem guarantees robust supply chain security and operational resilience throughout the development cycle. This strategic coordination underscores Asymchem’s ongoing commitment to translating its established small-molecule expertise into the TIDES domain, presenting itself as a dedicated, professional partner in the industry.

In conclusion, Asymchem’s introduction of the comprehensive TIDES commercial supply matrix signifies not only a major leap in peptide and oligonucleotide manufacturing but also reinforces the company’s position as a forward-thinking leader in the pharmaceutical manufacturing landscape. With its extensive capabilities, Asymchem is poised to collaborate closely with partners, navigating the complexities of drug development and ensuring reliable commercial supply for the rapidly evolving therapeutic landscape.

About Asymchem

Founded in 1995, Asymchem stands as a leading player in the global CDMO sector, focusing on integrated solutions for the pharmaceutical and biotech industries. With cutting-edge RD and manufacturing facilities located in China, the US, and Europe, Asymchem delivers a wide array of services, including small molecule development, biologics, and synthetic biology services. The company's commitment to innovation and sustainability continues to create significant value for its global clientele.